GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Thoratec Corp (FRA:TL1) » Definitions » Cyclically Adjusted PS Ratio

Thoratec (FRA:TL1) Cyclically Adjusted PS Ratio : (As of Jun. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Thoratec Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Thoratec Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Thoratec's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thoratec Cyclically Adjusted PS Ratio Chart

Thoratec Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Thoratec Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Thoratec's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Thoratec's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thoratec's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Thoratec's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Thoratec's Cyclically Adjusted PS Ratio falls into.



Thoratec Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Thoratec's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2015 is calculated as:

For example, Thoratec's adjusted Revenue per Share data for the three months ended in Jun. 2015 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2015 (Change)*Current CPI (Jun. 2015)
=2.075/100.6839*100.6839
=2.075

Current CPI (Jun. 2015) = 100.6839.

Thoratec Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200509 0.776 83.876 0.932
200512 0.863 83.032 1.046
200603 0.776 84.298 0.927
200606 0.812 85.606 0.955
200609 0.771 85.606 0.907
200612 0.848 85.142 1.003
200703 0.820 86.640 0.953
200706 0.780 87.906 0.893
200709 0.749 87.964 0.857
200712 0.743 88.616 0.844
200803 0.765 90.090 0.855
200806 0.849 92.320 0.926
200809 0.880 92.307 0.960
200812 0.975 88.697 1.107
200903 1.205 89.744 1.352
200906 1.150 91.003 1.272
200909 1.051 91.120 1.161
200912 1.238 91.111 1.368
201003 1.542 91.821 1.691
201006 1.171 91.962 1.282
201009 1.042 92.162 1.138
201012 1.267 92.474 1.379
201103 1.077 94.283 1.150
201106 1.221 95.235 1.291
201109 1.229 95.727 1.293
201112 1.381 95.213 1.460
201203 1.616 96.783 1.681
201206 1.589 96.819 1.652
201209 1.532 97.633 1.580
201212 1.645 96.871 1.710
201303 1.553 98.209 1.592
201306 1.702 98.518 1.739
201309 1.624 98.790 1.655
201312 1.611 98.326 1.650
201403 1.576 99.695 1.592
201406 1.519 100.560 1.521
201409 1.464 100.428 1.468
201412 1.871 99.070 1.901
201503 2.041 99.621 2.063
201506 2.075 100.684 2.075

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Thoratec  (FRA:TL1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Thoratec Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Thoratec's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Thoratec (FRA:TL1) Business Description

Traded in Other Exchanges
N/A
Address
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.

Thoratec (FRA:TL1) Headlines

No Headlines